ReviewInternational journal of nanomedicine2025
Key Nano-Strategies for Cisplatin Resistance in Advancing Anti-Cancer Therapy.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Lung cancer therapy using a chitosan-based nano drug discovery system of silver nanoparticles and chemotherapeutics.Discover oncology · 2026Article
- TMEM92 shields DDX3X from TTC3-mediated degradation to confer chemoresistance in triple-negative breast cancer.Clinical and translational medicine · 2026Article
- Combined Curcumin and Doxorubicin Induce Apoptosis via JNK-Dependent MAPK Signaling Independent of TXNDC5 in Human Osteosarcoma Cells.Nutrients · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cisplatin (CDDP) and other platinum-based agents remain cornerstones of cancer therapy. However, drug resistance severely impairs their clinical efficacy and therapeutic potential. Extensive research has identified diverse CDDP resistance mechanisms, broadly categorized as pre-target, on-target, off-target, and post-target resistance. These mechanisms exhibit substantial heterogeneity across patients and tumor types, highlighting the complexity of resistance development. Notably, resistance to other platinum drugs shares similarities with CDDP, presenting a common therapeutic challenge. Leveraging insights into CDDP resistance, personalized therapeutic strategies offer promise to enhance anti-tumor efficacy and overcome platinum resistance. The integration of nanotechnology and precision medicine has emerged as a pivotal frontier in oncology, where nanotechnology-based drug delivery systems (NDDSs) serve as multifunctional vectors for co-delivering CDDP and resistance-modulating agents. These intelligent platforms enable precise targeting and active circumvention of resistance mechanisms. This review comprehensively explores innovative NDDS strategies to overcome CDDP resistance, focusing on pre-target, on-target, off-target, and post-target mechanisms within a precision medicine framework. By synthesizing these advancements, we aim to provide a forward-looking perspective on NDDSs development and their potential to address the persistent challenge of platinum resistance in anti-cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.